Oceania Healthcare Ltd (OCA) fair value: what the stock is really worth
As of Nov 9, 2026: fair value (intrinsic value) of Oceania Healthcare Ltd stock A$0.88, price A$0.54, upside +64.5%, quality 48 out of 100. Rating: strongly undervalued. Calculated from audited financials with 14 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 7, 2026.
How to read this chart
60‑month range A$0.4750 – A$1.42 · fair‑value band A$0.6600 – A$1.16 · the A$0.5350 price screens below the A$0.8800 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 7, 2026.
Follow Oceania Healthcare in your weekly email
Every Wednesday you see whether Oceania Healthcare is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Oceania Healthcare Limited, together with its subsidiaries, owns and operates retirement villages and care centres in New Zealand. The company operates through Care Operations, Village Operations, and Others segments.
Show moreShow less
It provides traditional care beds and care suites; independent living and rental properties; and rest home, hospital, and specialist dementia services.
The company also offers accommodation, and care and related services to aged care residents, including meals and care packages to independent living residents; and accommodation and related services to independent residents in the retirement villages.
In addition, it is involved in the provision of support services and training activities. The company was formerly known as Retirement Care (NZ) Limited and changed its name to Oceania Healthcare Limited in September 2014.
Oceania Healthcare Limited was incorporated in 2005 and is based in Auckland, New Zealand.
Stock analysis
Oceania Healthcare Ltd (OCA) currently trades at A$0.5350, while our model-based Fair Value estimate is A$0.8800, implying the stock looks roughly 39% undervalued today.
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of A$1.14 per share, and 10 of the 13 models we run sit above the A$0.5350 price.
Bear case: the DCF Models group reads lowest at A$0.6300, and 3 of the 13 models stay below the price. Data coverage for this calculation is low.
Scenario range: A$0.6600 (bear) to A$1.16 (bull), the price of A$0.5350 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 48/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Oceania Healthcare Ltd reported revenue of 269M NZD in FY2026 versus 231M NZD in FY2022, a compound +3.9%/yr. Reported net income was 119K NZD in FY2026, compounding −79.0%/yr from FY2022.
Key figures
Market cap A$387M (≈ $267M) Micro · P/S ratio 1.46 · Net margin 0.0% · Return on equity 0.0% · Return on assets (EBIT) 2.3% (5-year average) · Operating margin −6.0% · Revenue (TTM) 269M NZD · Revenue growth (YoY) +7.6%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 17 out of 100 (low confidence).
What moves the price
The share trades about 35% below its 52-week high and 5% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −1% fair-value upside, at 64%, OCA screens cheaper than that median.
Fair Value models
BearA$0.6600Fair Value A$0.8800BullA$1.16
Price A$0.5350 · Upside +64.5%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.68/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+3.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.8%
Start year 2021 (pandemic). Over 10 years: +4.5% a year
Revenue growth 13 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.0%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
’26
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−73.5%
Earnings growth per share plus dividend.
Earnings per share, growth per year−73.5%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−73.5% vs −48.5%, slowing
Profit margin 2020 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−11% → −7%
Pace: the 5-year rate starts in 2021 (pandemic)
⚠ Revenue per share shrinking 3.5%/yr over ~10Y (margins intact) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far and less than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−6.6%
The company could shrink this much every year for the next five years and today's price would still be justified.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+5.7%
Yearly sales growth analysts expect, extended to five years.
After inflation (figures in NZD, New Zealand: IMF forecast 2.3% a year to 2030, 3.0% from 2016 to 2025) that is about −8.7% a year for the price and +3.4% for the forecasts.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 234 stocks
Beats the industry median on 4/11 measures
Overall it trails its industry peers.
Valuation
Quality Score48 · Below median
Fair Value upside+64.5% · Top 25%
Profitability
Return on equity (12 months)0.0% · Bottom 25%
Return on assets0.0% · Bottom 25%
Net margin (12 months)0.0% · Bottom 25%
Operating margin (12 months)−6.0% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)7.6% · Above median
Balance sheet
Debt / equity0.44× · Above median
Valuation Multiplesvs Medical Care Facilities median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Oceania Healthcare Ltd (OCA) overvalued or undervalued?
As of Nov 7, 2026, our model estimates a fair value of A$0.8800 versus a price of A$0.5350, about +64% upside (undervalued).
What is the fair value of OCA?
Our model-based fair value for Oceania Healthcare Ltd is A$0.8800 (as of Nov 7, 2026), built from audited fundamentals. The current price: A$0.5350.
What is the quality score of OCA?
Oceania Healthcare Ltd has a Quality Score of 48/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Oceania Healthcare Ltd (OCA)?
Our model-based price target is the fair value of A$0.8800 (as of Nov 7, 2026) from 14 valuation models. Cautious scenario A$0.6600, optimistic scenario A$1.16. It is a calculation from audited fundamentals, not an analyst target.
What is the Oceania Healthcare Ltd stock forecast for 2026?
Our models put fair value at A$0.8800, about +64% upside versus a price of A$0.5350 (undervalued). Cautious scenario A$0.6600, optimistic scenario A$1.16. The calculation is refreshed regularly with new filings.
What is the revenue of Oceania Healthcare Ltd (OCA)?
Oceania Healthcare Ltd reported trailing-twelve-month revenue of about 269M NZD (latest available figure, as of Nov 7, 2026).
What growth is priced into Oceania Healthcare Ltd (OCA)?
For today's price to be fair in a discounted-cash-flow model, Oceania Healthcare Ltd would have to grow free cash flow by -6.6 % per year for five years (discount rate 11.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +4.8 % per year. As of Nov 7, 2026.
What discount rate (WACC) does the fair value of OCA use?
Our models discount Oceania Healthcare Ltd at 11.3 %: a base by market capitalisation (micro), damped by beta 0.60, country premium for Australia. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Oceania Healthcare Ltd that is -6.6 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (11.3 %) and the same formula as our fair value.
How much growth has Oceania Healthcare Ltd (OCA) delivered so far?
Over the past 5 years revenue at Oceania Healthcare Ltd grew +4.8 % a year. The price currently implies free-cash-flow growth of -6.6 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Oceania Healthcare Ltd (OCA) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Oceania Healthcare Ltd (-6.6 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Oceania Healthcare Ltd (OCA)?
The free-cash-flow yield on the price is 29.41 %: that much free cash flow Oceania Healthcare Ltd produces per unit of market value. When it exceeds the discount rate of our models (11.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Oceania Healthcare Ltd (OCA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Oceania Healthcare Ltd it is A$0.8800 per share (as of Nov 7, 2026), against a price of A$0.5350. It is the blended result of 14 valuation models in 5 families (DCF Models, Multiples, Asset-Based, Growth DCF, Economic Profit).
Is Oceania Healthcare Ltd stock overvalued or undervalued in 2026?
As of Nov 7, 2026, OCA trades below its calculated fair value: price A$0.5350, fair value A$0.8800, a gap of about +64% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of OCA?
No. The price is what the market pays today (A$0.5350); the fair value is what the company's own numbers justify (A$0.8800). For Oceania Healthcare Ltd the two are A$0.3450 per share apart. That gap is exactly why we show both numbers side by side.
How much is Oceania Healthcare Ltd worth?
The market values Oceania Healthcare Ltd at about A$387M (market capitalisation, as of Nov 7, 2026). Per share that is A$0.5350; our models calculate a fair value of A$0.8800 per share.
What do the bullish and bearish scenarios say about OCA?
Our models span a range for Oceania Healthcare Ltd: cautious scenario A$0.6600, base A$0.8800, optimistic A$1.16 per share (as of Nov 7, 2026, price A$0.5350). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Oceania Healthcare Ltd (OCA)?
Balance-sheet figures for Oceania Healthcare Ltd (as of Nov 7, 2026): return on equity 0.0%, debt of 0.44 per unit of equity. They feed the Quality Score of 48/100, which measures business quality independently of the share price.
How far is OCA from its 52-week high?
Oceania Healthcare Ltd trades at A$0.5350, about 35% below its 52-week high of A$0.8200 and 5% above the low of A$0.5100 (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of A$0.8800 is for.
Which stocks are comparable to Oceania Healthcare Ltd?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Tenet Healthcare Corporation, Dr. Sulaiman Al Habib Medical Services Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Oceania Healthcare Ltd stock attractive at the current price?
The data as of Nov 7, 2026: price A$0.5350, calculated fair value A$0.8800 (+64%), Quality Score 48/100, from 14 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of OCA calculated?
We run Oceania Healthcare Ltd through 14 models from 5 families: DCF Models, Multiples, Asset-Based, Growth DCF, Economic Profit. Every model gets the same audited fundamentals; the fair value of A$0.8800 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Oceania Healthcare Ltd currently trades 39% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Oceania Healthcare Ltd (OCA)?
The closing price on Nov 9, 2026 was A$0.5350. Our model-based fair value is A$0.8800, about +64% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Oceania Healthcare Ltd right now?
The large discount to fair value meets weak quality (48/100). That raises the risk this is a value trap rather than a bargain. The price is below even our cautious bear case (A$0.6600). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Key figures of Oceania Healthcare Ltd
How large is the market capitalisation of Oceania Healthcare Ltd (OCA)?
The market capitalisation of Oceania Healthcare Ltd is A$387M (≈ $267M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Oceania Healthcare Ltd (OCA)?
The price-to-sales ratio of Oceania Healthcare Ltd is 1.46 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Oceania Healthcare Ltd (OCA)?
The net margin of Oceania Healthcare Ltd is 0.0% (last twelve months), excl. one-off gain FY2026 −1.9%. How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Oceania Healthcare Ltd (OCA)?
The return on equity (ROE) of Oceania Healthcare Ltd is 0.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Oceania Healthcare Ltd (OCA)?
On an EBIT basis the return on assets of Oceania Healthcare Ltd is 2.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Oceania Healthcare Ltd (OCA)?
The operating margin of Oceania Healthcare Ltd is −6.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Oceania Healthcare Ltd (OCA)?
Revenue at Oceania Healthcare Ltd is growing +7.6% versus a year earlier (3y avg +2.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Oceania Healthcare Ltd (OCA)?
Earnings per share at Oceania Healthcare Ltd are growing +210% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Oceania Healthcare Ltd (OCA) carry?
The net debt of Oceania Healthcare Ltd is 514M NZD (fiscal year 2026, ≈ 3.6 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Oceania Healthcare Ltd in the live analysis
One click puts Oceania Healthcare Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 7, 2026